Bispecific antibodies (bsAbs) are artificial antibodies engineered to contain two antigen-binding sites, allowing a single antibody molecule to simultaneously target multiple antigens. This enhances the killing function of tumor cells by interacting with target cells and effector cells. mRNA, capable of translating any protein in vivo, is harnessed to produce bsAbs. Utilizing mRNA technology for bsAbs synthesis results in reduced heterogeneity, such as insufficient glycosylation modifications observed in bsAbs produced by cell lines like CHO cells. This reduction in heterogeneity lowers clinical risks and significantly improves treatment efficacy for relevant diseases and the development of novel anti-tumor drugs. Research findings in this field are frequently published in top-tier academic journals such as Nature and Cell. EnoBio offers mRNA solutions for expressing bispecific antibodies, including mRNA sequence optimization for specific antibody sites and mRNA delivery, meeting the needs of customers in mRNA functionality and anti-tumor mechanism research, thereby facilitating the generation of high-quality scientific research outcomes.

EnoBio offers mRNA solutions for expressing bispecific antibodies, including mRNA sequence optimization for specific antibody sites and mRNA delivery, meeting the needs of customers in mRNA functionality and anti-tumor mechanism research, thereby facilitating the generation of high-quality scientific research outcomes.

case study:

Case One: Bridging Cells (T Cells with Tumor Cells)

By combining the coding sequences of antibodies CD3, which binds to T-cell receptors, and CLDN6, which binds to surface antigens on tumors, into a single mRNA chain, a BiTE-type bispecific antibody is expressed in vivo. This antibody brings effector T cells closer to tumor cells, inducing T-cell cytotoxicity. Mouse experiments have demonstrated its potent anti-tumor effects.

Case Two: Bridging Cells (NK Cells with Virus-Infected Cells)

By combining the coding sequences of antibodies FcγR4, which binds to NK cell receptors, and RSVF or M2e, which binds to surface antigens of influenza virus, into a single mRNA chain, a BiTE-type bispecific antibody is expressed in vivo. This antibody brings NK cells closer to virus-infected cells, leading to cytotoxic effects. Mouse experiments have shown significant improvement in mouse survival rates.

Case Three: Bridging Receptors (Dual Epitope Receptors)

By combining the coding sequences of antibodies targeting high-expressing epitopes CCL2 and CCL5 on tumor cell surfaces into a single mRNA chain, a bispecific antibody of the BiTE type is expressed in vivo. This antibody inhibits the activity of these epitopes, increases the sensitivity to PD-L1 therapy, and exhibits synergistic effects. Mouse experiments have demonstrated that bisCCL2/CCL5 can moderately inhibit tumor growth and, when used in conjunction with PD-L1, greatly enhances the anti-tumor effects.

1.Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. . 2017, 23(7):815.

2.mRNA Encoding a Bispecific Single Domain Antibody Construct Protects against Influenza A Virus Infection in Mice. . 2020 ,20:777.

3.mRNA Delivery of a Bispecific Single Domain Antibody to Polarize Tumor-associated Macrophages and Synergize Immunotherapy Against Liver Malignancies. . 2021,33(23):e2007603.